The role of L-3-1-123-iodine-α-methyl tyrosine-SPECT in cerebral gliomas

L-3-1-123-iodine-a-methyltyrosine (IMT) is a 1-123-labelled amino acid which has been used for single photon emission computed tomography (SPECT) of cerebral gliomas for more than a decade. IMT-SPECT is able to detect tumor infiltration independent of disruptions of the blood-brain barrier which is often difficult with computed tomography or magnetic resonance tomography. The method is useful to detect tumor recurrences and helps to distinguish gliomas from non-neoplastic brain masses. IMT-SPECT is thus a valuable tool in the diagnostic evaluation and in therapy planning of patients with cerebral gliomas.

Disturbance of serotonin 5HT2 receptors in remitted patients suffering from hereditary depressive disorder

Aim: The characteristics of 5HT2 receptor binding were investigated in major depression in vivo using positron emission tomography and the radioligand F-l 8-altanserin. Methods: Twelve patients from families with high loading of depression living in a geographically restricted region were examined and compared with normal control subjects. At the time of the PET measurement all patients were remitted; in some of them remission was sustained by antidepressive medication. Binding potential was assessed by Logan’s graphical analysis method. Results: The binding of F-l 8-altanserin was about 38% lower in patients than in healthy controls (p <0.00D. A multiple regression analysis revealed that this difference was mainly induced by depression rather than by medication. Conclusions: The data suggest that 5HT2 receptors are altered in depression. We present evidence for a reduction of the receptor density, which might be usable as trait marker of subjects susceptible for depressive illness.

High resolution BrainPET combined with simultaneous MRI

After the successful clinical introduction of PET/CT, a novel hybrid imaging technology combining PET with the versatile attributes of MRI is emerging. At the Forschungszentrum Jülich, one of four prototypes available worldwide combining a commercial 3T MRI with a newly developed BrainPET insert has been installed, allowing simultaneous data acquisition with PET and MRI. The BrainPET is equipped with LSO crystals of 2.5 mm width and Avalanche photodiodes (APD) as readout electronics. Here we report on some performance characteristics obtained by phantom studies and also on the initial BrainPET studies on various patients as compared with a conventional HR+ PET-only scanner. Material, methods: The radiotracers [18F]-fluoroethyl- tyrosine (FET), [11C]-flumazenil and [18F]-FP-CIT were applied. Results: Comparing komthe PET data obtained with the BrainPET to those of the HR+ scanner demonstrated the high image quality and the superior resolution capability of the BrainPET. Furthermore, it is shown that various MR images of excellent quality could be acquired simultaneously with BrainPET scans without any relevant artefacts. Discussion, conclusion: Initial experiences with the hybrid MRI/BrainPET indicate a promising basis for further developments of this unique technique allowing simultaneous PET imaging combined with both anatomical and functional MRI.

Cross-section measurements for the formation of manganese-52 and its isolation with a non-hazardous eluent

With respect to the production of no-carrieradded 52Mn nuclear reactions on natural chromium were investigated. Cross sections of the reactions natCr(p, x)48V, 48,49,51Cr, 52g,mMn were determined in the proton energy range of 7.6 to 45MeV. Additionally, production yields of 52g,mMn and 51Cr were measured in the energy range from 8.2 to 16.9MeV and therefrom the calculated saturation thick target yields were obtained as (2.55±0.31), (6.96±0.57), and (1.53±0.15) GBq/μA, respectively. For in vivo applications like PET, low toxicity is critical and sufficient activity of a radiolabelled compound mandatory. Thus, additional purification steps after separation of radionuclides and target materials have to be avoided. However, no isolation procedure has been reported in the literature so far where radiomanganese is directly obtained in a nonhazardous solution. Therefore a new separation procedure was developed utilizing the cation-exchange resin DOWEX 50W×8 (H+-form). 52gMn was quantitatively isolated from “bulk” chromium after 3 to 4 h in non-hazardous 0.067M ammonium citrate solution. Up to 99% of 52gMn activity was harvested within 10 to 15 mL eluent solution with no measureable 51Cr impurities.

Synthesis and preliminary pharmacological evaluation of a new putative radioiodinated AMPA receptor ligand for molecular imaging

A new (radio)iodinated AMPA receptor ligand has been developed and pharmacologically evaluated in vitro and ex vivo using rodents. The new radioligand was directly labeled by electrophilic radioiodo-destannylation with iodine- 131 in high radiochemical yields of 97% within 2 min. The new radioligand showed an excellent initial brain uptake of 2.1%ID/g at 10 min post injection, but a fast wash-out reduced the uptake by about 10-fold at 60 min post injection. Due to high nonspecific binding accompanied with a uniform distribution in brain tissue, however, the new radiotracer appears not suitable for AMPA receptor imaging in vivo.

[Perfusion brain imaging with SPECT-technique. German Guideline S1]

This paper describes the guideline for perfusion brain imaging with SPECT-technique published by the Association of the Scientific Medical Societies in Germany (AWMF).The purpose of this guideline is to provide practical assistance for indication, examination procedures, findings and their interpretation also reflecting the present state of the art. Information and instruction are given regarding indication, preparation of the patients and examination procedures of brain perfusion SPECT, including preparation and quality control of the tracer as well as the radiation dosimetry, technical performance of image acquisition with the gamma-camera and image processing. Also advices for interpretation of findings are given. In addition, possible pitfalls are described.

Hirnperfusions-SPECT mit 99mTc-Radiopharmaka

This paper describes the guideline for perfusion brain imaging with SPECT-technique published by the Association of the Scientific Medical Societies in Germany (AWMF). The purpose of this guideline is to provide practical assistance for indication, examination procedures, findings and their interpretation also reflecting the present state of the art. Information and instruction are given regarding indication, preparation of the patients and examination procedures of brain perfusion SPECT, including preparation and quality control of the tracer as well as the radiation dosimetry, technical performance of image acquisition with the gamma-camera and image processing. Also advices for interpretation of findings are given. In addition, possible pitfalls are described.

Integrated boost IMRT with FET-PET-adapted local dose escalation in glioblastomas. Results of a prospective phase II study

PURPOSE

Dose escalations above 60 Gy based on MRI have not led to prognostic benefits in glioblastoma patients yet. With positron emission tomography (PET) using [(18)F]fluorethyl-L-tyrosine (FET), tumor coverage can be optimized with the option of regional dose escalation in the area of viable tumor tissue.

METHODS AND MATERIALS

In a prospective phase II study (January 2008 to December 2009), 22 patients (median age 55 years) received radiochemotherapy after surgery. The radiotherapy was performed as an MRI and FET-PET-based integrated-boost intensity-modulated radiotherapy (IMRT). The prescribed dose was 72 and 60 Gy (single dose 2.4 and 2.0 Gy, respectively) for the FET-PET- and MR-based PTV-FET((72 Gy)) and PTV-MR((60 Gy)). FET-PET and MRI were performed routinely for follow-up. Quality of life and cognitive aspects were recorded by the EORTC-QLQ-C30/QLQ Brain20 and Mini-Mental Status Examination (MMSE), while the therapy-related toxicity was recorded using the CTC3.0 and RTOG scores.

RESULTS

Median overall survival (OS) and disease-free survival (DFS) were 14.8 and 7.8 months, respectively. All local relapses were detected at least partly within the 95% dose volume of PTV-MR((60 Gy)). No relevant radiotherapy-related side effects were observed (excepted alopecia). In 2 patients, a pseudoprogression was observed in the MRI. Tumor progression could be excluded by FET-PET and was confirmed in further MRI and FET-PET imaging. No significant changes were observed in MMSE scores and in the EORTC QLQ-C30/QLQ-Brain20 questionnaires.

CONCLUSION

Our dose escalation concept with a total dose of 72 Gy, based on FET-PET, did not lead to a survival benefit. Acute and late toxicity were not increased, compared with historical controls and published dose-escalation studies.

[German guidelines for brain tumour imaging by PET and SPECT using labelled amino acids]

For the primary diagnosis of brain tumours, morphological imaging by means of magnetic resonance imaging (MRI) is the current method of choice. The complementary use of functional imaging by positron emitting tomography (PET) and single photon emitting computerized tomography (SPECT) with labelled amino acids can provide significant information on some clinically relevant questions, which are beyond the capacity of MRI. These diagnostic issues affect in particular the improvement of biopsy targeting and tumour delineation for surgery and radiotherapy planning. In addition, amino acid labelled PET and SPECT tracers are helpful for the differentiation between tumour recurrence and non-specific post-therapeutic tissue changes, in predicting prognosis of low grade gliomas, and for metabolic monitoring of treatment response. The application of dynamic PET examination protocols for the assessment of amino acid kinetics has been shown to enable an improved non-invasive tumour grading. The purpose of this guideline is to provide practical assistance for indication, examination procedure and image analysis of brain PET/SPECT with labelled amino acids in order to allow for a high quality standard of the method. After a short introduction on pathobiochemistry and radiopharmacy of amino acid labelled tracers, concrete and detailed information is given on the several indications, patient preparation and examination protocols as well as on data reconstruction, visual and quantitative image analysis and interpretation. In addition, possible pitfalls are described, and the relevant original publications are listed for further information.

Excitation functions of α-particle induced reactions on enriched 123Sb and (nat)Sb for production of 124I

Excitation functions of (α,xn) reactions on 98.28% enriched (123)Sb and on (nat)Sb were measured from 9 to 40 MeV. The data could be described well in terms of statistical and precompound models using the code TALYS. The discrepancies in the literature data for the formation of (125)I and (126)I were solved. The nuclear reaction (123)Sb(α,3n)(124)I on an enriched target appears to be interesting for the production of (124)I (T(1/2)=4.18 d) over the energy range E(α)=42→32 MeV, its yield being 11.7 MBq/μAh. The levels of the radionuclidic impurities (125)I and (126)I amount to 1.8% and 0.6%, respectively. The use of (nat)Sb as target material for (124)I production is unsuitable due to the high level of (123)I impurity.

PET imaging problems with the non-standard positron emitters Yttrium-86 and Iodine-124

AIM

Positron emission tomography (PET) imaging of non-standard positron emitters is influenced by gamma-coincidences, i.e. false coincidences produced by the coincident detection of an annihilation photon and a gamma-ray simultaneously emitted with the positron. The extent to which the PET study is disturbed by this effect is dependent on the kind of the positron emitter used, the kind and position of the object, the acquisition mode, i.e. the optional use of septa, and the reconstruction program. In order to demonstrate and study imaging problems with non-standard positron emitters, a phantom was scanned containing non-radioactive rods with different absorption materials and filled with either (124)I or (86)Y in the bidimensional (2D) as well as tridimensional (3D) acquisition mode.

METHODS

For reconstruction, the PET manufacturer's standard software without any modification was used. To reduce errors caused by the gamma-coincidences, a simple linear background subtraction, estimated from the counts at the scanner's external radius, was applied.

RESULTS

Without background subtraction, apparent positive and negative ''radioactivity concentrations'' were found in regions of interest positioned over the non-radioactive rods with values higher for (86)Y compared to (124)I and also higher for 3D compared to 2D. A complete subtraction of the background led to erroneous

RESULTS

The errors in the phantom's non-radioactive rods and the difference between measured and true radioactivity became minimum, when about 75% of the background was subtracted. This refers to both the 2D and 3D mode.

CONCLUSION

Quantitation problems with the non-standard positron emitters (124)I and (86)Y could be minimized in the phantom study examined here by using a simple background subtraction together with the manufacturer's standard correction and reconstruction procedures.

Excitation functions of natGe(p,xn)71,72,73,74As reactions up to 100MeV with a focus on the production of 72As for medical and 73As for environmental studies

Excitation functions for the formation of the arsenic radionuclides (71)As, (72)As, (73)As and (74)As in the interaction of protons with (nat)Ge were measured from the respective threshold energy up to 100 MeV. The conventional stacked-foil technique was used and the needed thin samples were prepared by sedimentation. Irradiations were done at three cyclotrons: CV 28 and injector of COSY at Forschungszentrum Jülich, and Separate Sector Cyclotron at iThemba LABS, Somerset West. The radioactivity was measured via high-resolution gamma-ray spectrometry. The measured cross section data were compared with the literature data as well as with the nuclear model calculations. In both cases, the results generally agree but there are discrepancies in some areas, the results of nuclear model calculation and some of the literature data being somewhat higher than our data. The integral yields of the four radionuclides were calculated from the measured excitation functions. The beta(+) emitting nuclide (72)As (T(1/2)=26.01 h) can be produced with reasonable radionuclidic purity ((71)As impurity: <10%) over the energy range E(p) = 18-->8 MeV; the yield of 93 MBq/microAh is, however, low. The radionuclide (73)As (T(1/2)=80.30 d), a potentially useful indicator in environmental studies, could be produced with good radionuclidic purity ((74)As impurity: <11%) over the energy range E(p) = 30 --> 18 MeV, provided, a decay time of about 60 days is allowed. Its yield would then correspond to 2.4 MBq/microAh, and GBq amounts could be produced when using a high current target.

Yield and purity of 82Sr produced via the natRb(p,xn)82Sr process

The recently reported cross-section data for the production of 82Sr via the natRb(p,xn) 82Sr process were evaluated. For the natRb(p,xn) 85Sr process, cross-sections were measured experimentally over the proton energy range of 25-45 MeV, a region where very few data existed. An evaluation of the recently published data on the formation of 85Sr was then also performed. From the recommended data curves, the integral yields of the desired radionuclide 82Sr and the impurity 85Sr were calculated. Yields were also determined experimentally over several energy ranges using thick natRbCl targets. The experimental and calculated yields were found to be in agreement within 15%. These integral tests add confidence to the evaluated cross-section data. For the production of 82Sr, an incident proton energy of 60 MeV or above is recommended; the 85Sr impurity then corresponds to <20%.

Evaluation of novel tropane analogues in comparison with the binding characteristics of [18F]FP-CIT and [131I]β-CIT

This study evaluated novel potential dopamine transporter (DAT) inhibitors as ligands for positron emission tomography. Five new tropane analogs were synthesized and compared with the known ligand 2beta-carbomethoxy-3beta-(4-iodophenyl)tropane (beta-CIT) and the recently characterized ligands N-(3-iodoprop-2E-enyl)-2beta-carbomethoxy-3beta-(4-methylphenyl)-nortropane (PE2I) and 2beta-carbofluoroethoxy-3beta-(4-methylphenyl)tropane (FETT). Evaluation with autoradiography measured the ability to antagonize the binding of [(131)I]iodine-labeled beta-CIT and [(18)F]fluorine-labeled N-(3-fluoropropyl)-2beta-carbomethoxy-3beta-(4-iodo-phenyl) nortropane in rat and pig brains. The standards for comparison (PE2I and FETT) competed strongly in all regions investigated (striatum, cortex, superior colliculus and cerebellum). Of the new compounds, 2alpha-amido-fluoroethyl-3beta-(4-iodophenyl)tropane (4) and 2beta-amido-fluoroethyl-3beta-(4-iodophenyl)tropane (4a) competed strongly with [(131)I]beta-CIT in DAT-rich striatum, but also in other brain regions suggesting poor DAT selectivity. Because [(131)I]beta-CIT binds unselectively both to DAT and serotonin transporters, no definite conclusion about the selectivity of the new compounds is possible. However, preclinical studies using the compounds and labeled with fluorine-18 or iodine-131 are encouraged.

Excitation functions of (alpha,xn) reactions on (nat)Rb and (nat)Sr from threshold up to 26 MeV: possibility of production of (87)Y, (88)Y and (89)Zr

Excitation functions were measured by the stacked-foil technique for (nat)Rb(alpha,xn)(87m,87m+g,88)Y and (nat)Sr(alpha,xn)(86,88,89)Zr reactions from their respective thresholds up to 26 MeV. The samples for irradiation were prepared by sedimentation and pellet pressing techniques. The measured data were compared with those available in the literature. From the excitation functions, integral yields of the products were calculated. The suitable energy ranges for the production of (87)Y and (88)Y via (nat)Rb(alpha,xn) processes and of (89)Zr via the (nat)Sr(alpha,xn) process are E(alpha)=26-->20 MeV, E(alpha)=26-->5 MeV and E(alpha)=20-->8.5 MeV, respectively. The respective yields amount to 8.2, 0.08 and 0.9 MBq/microA h. Production of (88)Y is feasible if a waiting time of about 2 months is allowed to let the impurities decay out. Also, (87)Y can be produced with a relatively low impurity of (88)Y. The yields of both (88)Y and (87)Y via the present routes are, however, appreciably lower than those via the (nat)Sr(p,xn) processes. There is a possibility to produce (89)Zr via the alpha-particle irradiation of (nat)Sr. The yield is rather low but would be considerably increased if enriched (86)Sr would be used as target material. The radionuclidic impurity levels in all the three products are discussed.

Fluorine-18 labeling methods: Features and possibilities of basic reactions

Many experimental and established tracers make fluorine- 18 the most widely used radionuclide in positron emission tomography with an increasing demand for new or simpler 18F-labeling procedures. After a brief summary of the advantages of the nuclide and its major production routes, the basic features of the principal radiofluorination methods are described. These comprise direct electrophilic and nucleophilic processes, or in case of more complex molecules, the labeling of synthons and prosthetic groups for indirect built-up syntheses. While addressing the progress of no-carrier-added 18F-labeling procedures, the following chapters on more specific topics in this book are introduced. Emphasis is given to radiofluorination of arenes--especially with iodonium leaving groups. Examples of radiopharmaceutical syntheses are mentioned in order to illustrate strategic concepts of labeling with fluorine-18.

No-carrier-added nucleophilic 18F-labelling in an electrochemical cell exemplified by the routine production of [18F]altanserin

A new type of electrochemical cell with anodic deposition of no-carrier-added [(18)F]fluoride and variable reaction volume has been developed. The reactor is designed for small reaction volumes and non-thermal drying of [(18)F]fluoride. The implementation of this reactor into a complete remotely controlled synthesis device is described for the routine production of [(18)F]altanserin. A radiochemical yield of 23+/-5% was obtained via cryptate-mediated nucleophilic (18)F-fluorination. Batches of up to 6 GBq [(18)F]altanserin, suitable for human application, with a molar activity of >500 GBq/micromol were obtained within 75 min.

Assessment of the short-lived non-pure positron-emitting nuclide (120)I for PET imaging

PURPOSE

The non-pure positron-emitting iodine isotope (120)I (T(1/2)=81 min) is a short-lived alternative to (124)I. (120)I has a positron abundance more than twice that of (124)I and a maximum positron energy of 4 MeV. This study was undertaken to evaluate and characterise the qualitative and quantitative PET imaging of (120)I.

METHODS

(120)I was produced via the (120)Te(p,n) reaction on highly enriched (120)Te. The measurements were done with the Siemens scanner HR+ and the 2D PET scanner GE PC4096+. A cylinder containing three cold inserts and a phantom resembling a human brain slice were used to evaluate half-life, positron abundance and background correction. To analyse the image resolution, a -mm tube placed in water was filled with (120)I and (18)F. Comparisons with (18)F, (124)I and (123)I (measured with SPECT) were made using the Hoffman 3D brain phantom.

RESULTS

The half-life of 81.1 min was reproduced by the PET measurements. The PET-based positron abundance ranged from 47.9% to 55.0%. The reconstructed image resolution found with the HR+ was 5.4 mm FWHM (12.3 mm FWTM), in contrast to 4.6 mm (8.6 mm) when using (18)F. Erroneous positive and negative numbers of radioactivity found in the cold inserts became nearly zero when the background of gamma-coincidences was corrected for. Images of the Hoffman phantom were inferior to those obtained when (18)F or (124)I was applied but superior to the (123)I-SPECT images.

CONCLUSION

Our data show that (120)I of high radionuclidic purity can be regarded as a suitable nuclide for the PET imaging of radioiodine-labelled pharmaceuticals.

Nuclear data for production of the therapeutic radionuclides 32P, 64Cu, 67Cu, 89Sr, 90Y and 153Sm via the (n,p) reaction: evaluation of excitation function and its validation via integral cross-section measurement using a 14 MeV d(Be) neutron source

Nuclear data for production of the therapeutic radionuclides 32P, 64Cu, 67Cu, 89Sr, 90Y and 153Sm via (n,p) reactions on the target nuclei 32S, 64Zn, 67Zn, 89Y, (90)Zr and 153Eu, respectively, are discussed. The available information on each excitation function was analysed. From the recommended data set for each reaction the average integrated cross section for a standard 14 MeV d(Be) neutron field was deduced. The spectrum-averaged cross section was also measured experimentally. A comparison of the integrated value with the integral measurement served to validate the excitation function within about 15%. A fast neutron source appears to be much more effective than a fission reactor for production of the above-mentioned radionuclides in a no-carrier-added form via the (n,p) process. In particular, the possibility of production of high specific activity 153Sm is discussed.

(3)He-particle-induced reactions on (nat)Sb for production of (124)I

Excitation functions of the reactions (nat)Sb((3)He,xn)(124,123,121)I were measured from their respective thresholds up to 35 MeV, with particular emphasis on data for the production of the medically important radionuclide (124)I. The conventional stacked-foil technique was used. From the experimental data the theoretical yields of the three investigated radionuclides were calculated. The yield of (124)I over the energy range E9(30He) = 35 --> 13 MeV amounts to 0.95 MBq/microA h. The radionuclidic impurities are discussed. A comparison of (3)He- and alpha-particle-induced reactions on antimony for production of (124)I is given. The alpha-particle-induced reaction on enriched (121)Sb and the (3)He-particle-induced reaction on enriched (123)Sb would lead to comparable (124)I yields, but the level of impurities in the latter case would be somewhat higher.

Alpha-particle induced reactions on natSb and 121Sb with particular reference to the production of the medically interesting radionuclide 124I

Excitation functions of the reactions (nat)Sb(alpha,xn)(123,124,125,126)I and (121)Sb(alpha,xn)(123,124)I were measured from their respective thresholds up to 26 MeV, with particular emphasis on data for the production of the medically important radionuclide (124)I. The conventional stacked-foil technique was used, and the samples for irradiation were prepared by a sedimentation process. The measured excitation curves were compared with the data available in the literature. From the experimental data the theoretical yields of the investigated radionuclides were calculated as a function of the alpha-particle energy. The calculated yield of (124)I from the (nat)Sb(alpha,xn)(124)I process over the energy range E(alpha) = 22-->13 MeV amounts to 1.02 MBq/microA x h and from the (121)Sb(alpha,n)(124)I reaction over the same energy range to 2.11 MBq/microA x h. The radionuclidic impurity levels are discussed. Use of (nat)Sb as target material would not lead to high-purity (124)I. Using highly enriched (121)Sb as target, production of (124)I of high radionuclidic purity is possible; the batch yield, however, is low.

Cross-section measurement of the 169Tm(p,n) reaction for the production of the therapeutic radionuclide 169Yb and comparison with its reactor-based generation

The radionuclide (169)Yb (T(1/2)=32.0 d) is potentially important for internal radiotherapy. It is generally produced using a nuclear reactor. In this work the possibility of its production at a cyclotron was investigated. A detailed determination of the excitation function of the (169)Tm(p,n)(169)Yb reaction was done over the proton energy range up to 45 MeV using the stacked-foil technique and high-resolution gamma-ray spectrometry. The integral yield of (169)Yb was calculated. Over the optimum energy range E(P)=16-->7 MeV the yield amounts to 1.5 MBq/micro Ah and is thus rather low. A comparison of this production route with the established (168)Yb(n,gamma)(169)Yb reaction at a nuclear reactor is given. The (169)Yb yield via the reactor route is by several orders of magnitude higher than by the cyclotron method. The latter procedure, however, leads to "no-carrier-added" product.

Bilateral subdural haematomata and lumbar pseudomeningocele due to a chronic leakage of liquor cerebrospinalis after a lumbar discectomy with the application of ADCON-L gel

The anti-adhesion gel ADCON-L has been available since the end of the 1990s. During disc surgery it can be applied to the spinal nerve roots and the dura mater spinalis in order to inhibit fibroblast migration and thus avoid postoperative adhesions or excessive keloids, respectively. Due to the way ADCON-L works, inadvertent, intraoperational dural lesions may stay open much longer than usual because ADCON-L inhibits the natural healing process. Possible consequences are a chronic leakage of cerebrospinal fluid in combination with intracranial hypotension syndrome. We report on a patient who underwent lumbar disc surgery with application of ADCON-L gel. Postoperatively he suffered from acute headache, nausea, and vomiting. A lumbar pseudomeningocele was demonstrated on magnetic resonance imaging (MRI). Furthermore, cranial MRI revealed bilateral, chronic subdural haematomata which indicated intracranial hypotension syndrome or continuous leakage of cerebrospinal fluid at the lumbar site. With conservative treatment the problems were gradually reduced and eventually the subdural haematomata were no longer detected. The pseudomeningocele persisted over a 4 month period of observation. Because of the complications we found, the local application of ADCON-L during lumbar disc surgery should be critically evaluated.

Labelling of manganese-based magnetic resonance imaging (MRI) contrast agents with the positron emitter 51Mn, as exemplified by manganese-tetraphenyl-porphin-sulfonate (MnTPPS4)

The potential tumor seeking MRI contrast agent MnTPPS(4) was labelled with the positron emitting nuclide (51)Mn in no-carrier-added (n.c.a.) form. The complex formation kinetics were investigated and the apparent rate constants were determined under pseudo-first-order conditions. The derived bimolecular rate constants gave the Arrhenius parameters E(A)=84 kJ mol(-1) and A=2 x 10(12)s(-1)M(-1). Optimum labelling conditions were derived (radiochemical yields >99% possible, effective yields about 32%). Separation and purification of n.c.a. (51)MnTPPS(4) were performed for potential human use. All impurities were <1%.

O-(2-[18F]fluorethyl)-L-tyrosine PET in the clinical evaluation of primary brain tumours

PURPOSE

The aim of this study was to evaluate the differential uptake of O-(2-[18F]fluorethyl)-L-tyrosine (FET) in suspected primary brain tumours.

METHODS

Positron emission tomography (PET) was performed in 44 patients referred for the evaluation of a suspected brain tumour. Acquisition consisted of four 10-min frames starting upon i.v. injection of FET. Tumour uptake was calculated as the ratio of maximal tumour intensity to mean activity within a reference region (FETmax).

RESULTS

FET uptake above the cortical level was observed in 35/44 lesions. All histologically confirmed gliomas and many other lesions showed FET uptake to a variable extent. No uptake was observed in nine lesions (one inflammatory lesion, one dysembryoplastic neuroepithelial tumour, one mature teratoma, six lesions without histological confirmation). An analysis of uptake dynamics was done in the patients with increased FET uptake (22 gliomas, three lymphomas, three non-neoplastic lesions, three lesions with unknown histology and four other primaries). Upon classification of tumours into low (i.e. WHO I and II) and high grade (i.e. WHO III and IV), a significant difference in FETmax between the two categories was observed only in the first image frame (0-10 min p.i.), with FETmax=2.0 in low-grade and 3.2 in high-grade tumours (p<0.05); no significant differences were found in frame 4 (30-40 min p.i.), with FETmax=2.4 vs 2.7. Similar results were obtained when the analysis was applied only to astrocytic tumours (2.0 vs 3.1 in the first frame; 2.4 vs 2.6 in the fourth frame).

CONCLUSION

These initial results indicate that FET PET is a useful method to identify malignant brain lesions. It appears that high- and low-grade brain tumours exhibit a different uptake kinetics of FET. A kinetic analysis of FET PET may provide additional information in the differentiation of suspected brain lesions.

Binding of tritiated and radioiodinated ZM241,385 to brain A2A adenosine receptors

Autoradiography on rat brain using tritiated (1*), mono- (2*) and di-radioiodinated (3*) derivatives of the A(2A) adenosine receptor antagonist ZM241,385 showed high receptor density in striatum. K(D)s of 1*, 2* and 3* were 0.4, 2.2 and 15 nM and nonspecific binding was 5, 40 and 50% of total binding. Striatal uptake of 2* in mice was approximately 0.2% ID/g 60 min post-injection; blocking by 2 was insignificant. Poor penetration of the blood brain barrier and high nonspecific binding make 2* unsuitable for imaging striatal receptors.

Formation of short-lived positron emitters in reactions of protons of energies up to 200 MeV with the target elements carbon, nitrogen and oxygen

Excitation functions were measured by the stacked-foil technique for proton induced reactions on carbon, nitrogen and oxygen leading to the formation of the short-lived positron emitters (11)C (T(1/2) = 20.38 min) and (13)N (T(1/2) = 9.96 min). The energy region covered extended up to 200 MeV. The product activity was measured non-destructively via gamma-ray spectrometry. A careful decay curve analysis of the positron annihilation radiation was invariably performed. The experimental results were compared with theoretical data obtained using the modified hybrid nuclear model code ALICE-IPPE for intermediate energies. The agreement was found to be generally satisfactory. The data are of importance in proton therapy.

Experimental studies and nuclear model calculations on proton-induced reactions on natSe, 76Se and 77Se with particular reference to the production of the medically interesting radionuclides 76Br and 77Br

Excitation functions of the reactions (nat)Se(p,x)(75,76,77,82)Br, (76)Se(p,xn)(75,76)Br, (76)Se(p,x)(75)Se and (77)Se(p,xn)(76,77)Br were measured from their respective thresholds up to 40 MeV, with particular emphasis on data for the production of the medically important radionuclides (76)Br and (77)Br. The conventional stacked-foil technique was used. The samples were prepared by a sedimentation process. Irradiations were performed using the compact cyclotron CV 28 and the injector of COSY, both at the Research Centre Jülich. In order to validate the data, nuclear model calculations were performed using the code ALICE-IPPE which is based on the preequilibrium-evaporation model. Good agreement was found between the experimental and theoretical data, except in the high-energy region where the calculated data were somewhat higher. All the measured excitation curves were compared with the data available in the literature. From the experimental data the theoretical yields of all the investigated radionuclides were calculated and plotted as a function of proton energy. The calculated yield of (77)Br from the (nat)Se(p,x)(77)Br process over the energy range E(p)=25-->15 is 72.7 MBq/microAh and from the (77)Se(p,n)(77)Br reaction over E(p)=15-->6 MeV it is 86.2 MBq/microAh. The yield of (76)Br from the (76)Se(p,n)(76)Br reaction for E(p)=15-->8 is 360.1 MBq/microAh and from the (77)Se(p,2n)(76)Br reaction for E(p)=28-->18 MeV it is 879.2 MBq/microAh. The radionuclidic impurity levels are discussed.

Cross-section measurements of the nuclear reactions natZn(d,x)64Cu, 66Zn(d,alpha)64Cu and 68Zn(p,alphan)64Cu for production of 64Cu and technical developments for small-scale production of 67Cu via the 70Zn(p,alpha)67Cu process

The radionuclides 64Cu (T1/2=12.7h) and 67Cu (T1/2=61.9h) are useful in internal therapy. In connection with production of 64Cu, excitation functions of the reactions natZn(d,x)64Cu, 66Zn(d,alpha)64Cu and 68Zn(p,alphan)64Cu were measured radiochemically using the stacked-foil technique. From the measured data, the thick target yields of 64Cu were calculated and compared with experimental data available in the literature. The three investigated processes are discussed in comparison to the commonly used 64Ni(p,n)64Cu reaction for the production of 64Cu. As regards 67Cu production, the technical feasibility of the 70Zn(p,alpha)67Cu process was investigated. An electroplated isotopically enriched 70Zn target was developed which can withstand slanting beams of 20MeV protons of currents up to 20 microA. Methods for chemical separation of 67Cu and efficient recovery of the enriched target material were worked out. The method is suitable only for small-scale production of 67Cu.

Evaluation of radioiodinated 8-Cyclopentyl-3-[(E)-3-iodoprop-2-en-1-yl]-1-propylxanthine ([*I]CPIPX) as a new potential A1 adenosine receptor antagonist for SPECT

8-Cyclopentyl-3-[(E)-3-[(131)I]iodoprop-2-en-1-yl]-1-propylxanthine (2*) was generated by iododestannylation of the tributyl-stannyl-precursor with [(131)I]NaI and chloramine T. The radiochemical yield of 2* was 82 +/- 4%, and the purity exceeded 98%. The specific activity was 33 +/- 19 GBq/micromol. Affinities for rat, pig and human A(1) adenosine receptors (A(1)ARs) were in the low nanomolar range, but poor selectivity for the human A(1)AR over the A(2A)AR was found. Additionally, in vitro and ex vivo autoradiographic studies revealed high unspecific binding which makes this ligand unsuitable for SPECT imaging.

Radiosynthesis and in vitro stability evaluation of various radioiodine-labelled beta-iodoalkylether prosthetic groups linked to model compounds

A systematic comparative investigation into the in vitro radiochemical stabilities of model compounds containing radioiodinated beta-iodoethoxyl units and derivatives thereof, as well as those of similar compounds lacking a beta-oxygen to serve as control references, was undertaken. The radioiodinations were carried out in fair to modest yields by means of substitution of a tosyl group by iodide. Stability evaluations were carried out by incubating the labeled compounds in human blood serum at 37 degrees C and measuring free radioiodide by means of radio-HPLC and radio-TLC. The compounds containing beta-iodoethoxyl units displayed much superior stabilities than those without, while the presence of small alkyl or aryl groups in such a unit rendered an additional degree of stability to the carbon-iodine bond, especially over a long period.

Some optimisation studies relevant to the production of high-purity 124I and 120gI at a small-sized cyclotron

Optimisation experiments on the production of the positron emitting radionuclides 124I(T(1/2) = 4.18d) and (120g)I (T(1/2) = 1.35 h) were carried out. The TeO(2)-target technology and dry distillation method of radioiodine separation were used. The removal of radioiodine was studied as a function of time and the loss of TeO(2) from the target as a function of oven temperature and time of distillation. A distillation time of 15 min at 750 degrees C was found to be ideal. Using a very pure source and comparing the intensities of the annihilation and X-ray radiation, a value of 22.0 +/- 0.5% for the beta(+) branching in 124I was obtained. Production of 124I was done using 200 mg/cm(2) targets of 99.8% enriched 124TeO(2) on Pt-backing, 16 MeV proton beam intensities of 10 microA, and irradiation times of about 8 h. The average yield of 124I at EOB was 470 MBq(12.7 mCi). At the time of application (about 70 h after EOB) the radionuclidic impurity 123I (T(1/2) = 13.2 h) was <1%. The levels of other impurities were negligible (126I < 0.0001%;125I = 0.01%). Special care was taken to determine the 125I impurity. For the production of (120g)I only a thin 30 mg target (on 0.5 cm(2) area) of 99.9% enriched 120TeO(2) was available. Irradiations were done with 16 MeV protons for 80 min at beam currents of 7 microA. The 120gI yield achieved at EOB was 700 MBq(19 mCi), and the only impurity detected was the isomeric state 120 mI(T(1/2) = 53 min) at a level of 4.0%. The radiochemical purity of both 124I and 120gI was checked via HPLC and TLC. The radioiodine collected in 0.02 M NaOH solution existed >98% as iodide. The amount of inactive Te found in radioiodine was <1 microg. High purity 124I and 120gI can thus be advantageously produced on a medium scale using the low-energy (p,n) reaction at a small-sized cyclotron.

Efficient routine production of the 18F-labelled amino acid O-2-18F fluoroethyl-L-tyrosine

A convenient remotely controlled no-carrier-added synthesis of enantiomerically pure O-(2-[18F]fluoroethyl)-L-tyrosine (FET) is described. This allows the distribution of the radiotracer to other laboratories according to the satellite concept. The radiochemical yield obtained within 80 min is about 60%. The FET containing HPLC fraction can be used immediately (after adding sodium chloride) for human application.

[The (11C) acetate positron emission tomography in prostatic carcinoma. New prospects in metabolic imaging]

The exact staging of prostate cancer is mandatory to allow selection of the appropriate primary therapy. In addition, if the PSA level rises again it is extremely important to find the site(s) of local recurrence or metastatic spread as soon as possible. However, with the morphological and metabolic imaging techniques currently available it is often not possible to answer these questions with adequate sensitivity and specificity, since small metastases < or = 1 cm in diameter are likely to remain undetected by them. In the last few years new radioactive labelled tracers have been introduced for use in positron emission tomography (PET), and it is hoped that the shortcomings in the diagnostic procedures used for prostate carcinoma might be compensated by their use. Besides 11C- or 18F-labelled choline, [11C]Acetate is also attracting attention as a promising PET tracer. In this paper we review the various PET tracers available and evaluate the advantages and the drawbacks of [11C]Acetate in three case studies by comparing [11C]Acetate-PET with histology and with other imaging techniques. The use of [11C]Acetate appears to be feasible and helpful in the diagnosis of prostate carcinoma. However, its final value relative to other imaging techniques needs further investigation, with special reference to initial lymph node involvement, early localisation of recurrence and possible noninvasive differentiation between prostate cancer, prostatis and benign hyperplasia of the prostate.

Distribution of 5HT2A receptors in the human brain: comparison of data in vivo and post mortem

AIM

The study presented here firstly compares the distribution of the binding potential of the serotonin-5HT2A receptor as measured in vivo with data of receptor density taken from literature. Secondly, the sensitivity of the method to detect gradual differences in receptor densities is evaluated.

METHODS

Positron emission tomography (PET) studies were carried out in 6 healthy volunteers using the selective serotonin-5HT2A ligand 18F-altanserin. The binding potential was quantified in 12 regions using Logan's graphical method and the equilibrium method. These data were compared to the distribution of receptor density as taken from literature.

RESULTS

The binding data in vivo correlated to autoradiography data (post mortem) with r = 0.83 (Pearson regression coefficient; p < 0.0001). A difference in the receptor density between two regions could be detected with p < 0.05 when it amounted at least to 18%.

CONCLUSION

This study demonstrates a good agreement between in vivo data obtained with 18F-altanserin and PET in healthy volunteers and the true autoradiographically determined distribution of 5HT2A receptors in human brains. The in vivo method seems to be sensitive enough to detect changes in receptor density of more than 18%.

Synthesis of 2-[18F]fluoro-L-tyrosine via regiospecific fluoro-de-stannylation

2-[18F]Fluoro-L-tyrosine is a fluorine labelled amino acid, known to be incorporated into newly synthesised proteins, rendering it a potentially suitable tracer to image protein metabolism in vivo using positron emission tomography. For the electrophilic preparation of 2-[18F]fluoro-L-tyrosine three protected 2-trialkylstannyl tyrosine derivatives have been synthesised for the first time as precursors. While O,N-di-Boc-2-triethylstannyl-L-tyrosine ethylester has proved to be suitable as precursor for radiosynthesis, imidazolidinon-derivatives of 2-triaklylstannyl tyrosine have not because of difficult fast hydrolysis of a phenolic O-methyl protective group. The di-Boc-tin derivative of tyrosine ethylester readily reacted with [18F]F2, which was prepared via the 18O(p,n)18F nuclear reaction. 2-[18F]Fluoro-L-tyrosine was isolated after full deprotection with aqueous hydrobromic acid and HPLC purification with activities of 1.41 +/- 0.32GBq. The isomeric and enantiomeric purity is high (both >99%). The preparation procedure is facile and easy to automate. The chemical yields of this fluoro-de-stannylation reaction as well as of the synthesis of 6-[18F]fluoro-L-dopa, determined with an analogous precursor and non-radioactive fluorine under identical conditions, amounted to 42.7 +/- 1.6% and 60.2 +/- 2.8%, respectively.